Meeting
2022 ASCO Annual Meeting
Association of early tumor growth rate and survival outcomes in first-line metastatic non–small cell lung cancer (mNSCLC).
Authors
Antonio Tito Fojo
Columbia University College of Physicians and Surgeons, New York, NY
Antonio Tito Fojo , Kevin Brown , Diederik J. Grootendorst , SRIVIDYA KOTAPATI , Matthew Fronheiser , Phuong Tran , Jasmine I. Rizzo , David Leung , Mariann Micsinai Balan , No Firstname Kald.Abdallah@Bms.Com , Binsheng Zhao , Lawrence Howard Schwartz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9063)
DOI
10.1200/JCO.2022.40.16_suppl.9063
Abstract #
9063
Poster Bd #
51
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.
First Author: Luis G. Paz-Ares
Poster
2022 ASCO Annual Meeting
Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227.
First Author: Julie R. Brahmer
Poster
2021 ASCO Annual Meeting
Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.
First Author: Luis G. Paz-Ares
Poster
2023 ASCO Annual Meeting
Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R).
First Author: Patrick M. Forde